# Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

> **NCT01645215** · PHASE1 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 40 (actual)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT01645215
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01645215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01645215, "Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01645215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*